Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 10/2017

26.05.2017 | Original Article

Why does measles persist in Europe?

verfasst von: P. Plans-Rubió

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Several reasons may explain why measles was not eliminated by 2015 and continues to persist in Europe, including low measles vaccination coverage, low anti-measles herd immunity levels, and the mobility of individuals with measles across Europe. The study assessed the mean measles vaccination coverage in the European Union and the WHO European region with one and two doses of measles vaccine from 1980 to 2015, and the prevalence of vaccine-induced protected individuals and anti-measles herd immunity levels in the WHO European region during 2000–2015. The study found that measles vaccination coverage with two doses of vaccine was <90% in the European Union and the WHO European region from 1995 to 2015. In the WHO European region, the two-dose measles vaccination coverage during the 2000–2015 period was <95% in 41 countries (79%), and the prevalence of vaccine-induced protected individuals in the target vaccination population was lower than the herd immunity threshold of 94.4% in 33 countries (63%). The additional vaccination coverage required to establish herd immunity in these countries ranged from 0.2% to 18%. Two of the factors explaining measles persistence in Europe in 2015 were the two-dose measles vaccination coverage <95% and the prevalence of individuals with vaccine-induced protection of <94.4% in most countries of the WHO European region during the 2000–2015 period. Screening and vaccination programs should be developed to detect and immunize susceptible individuals in areas and population groups without anti-measles herd immunity in all European countries.
Literatur
11.
Zurück zum Zitat Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, Oxford Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, Oxford
12.
Zurück zum Zitat Gay NJ (2004) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189 [Suppl 1]:S27−S35CrossRefPubMed Gay NJ (2004) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189 [Suppl 1]:S27−S35CrossRefPubMed
13.
Zurück zum Zitat Plans-Rubió P (2012) Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 8:184–188CrossRefPubMed Plans-Rubió P (2012) Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 8:184–188CrossRefPubMed
14.
Zurück zum Zitat Plans-Rubió P (2010) Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunisation strategies. Med Decis Making 30:438–443CrossRef Plans-Rubió P (2010) Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunisation strategies. Med Decis Making 30:438–443CrossRef
15.
Zurück zum Zitat Hinman AR, Urquhart GA, Strikas RA (2007) Immunization information systems. National Vaccine Advisory Committee progress report, 2007. J Public Health Manag Pract 13:553–558CrossRefPubMed Hinman AR, Urquhart GA, Strikas RA (2007) Immunization information systems. National Vaccine Advisory Committee progress report, 2007. J Public Health Manag Pract 13:553–558CrossRefPubMed
16.
Zurück zum Zitat Muller CP, Kremer JR, Best JM, Dourado I, Triki H, Reef S, WHO Steering Committee for Measles and Rubella (2007) Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 25:1–9CrossRefPubMed Muller CP, Kremer JR, Best JM, Dourado I, Triki H, Reef S, WHO Steering Committee for Measles and Rubella (2007) Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 25:1–9CrossRefPubMed
17.
Zurück zum Zitat Plans P (2013) New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis 32:961–996CrossRefPubMed Plans P (2013) New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis 32:961–996CrossRefPubMed
18.
Zurück zum Zitat Rota PA, Brown K, Mankertz A, Santibanez S, Shulga S, Muller CP et al (2011) Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis 204 [Suppl 1]:S514–S523CrossRefPubMed Rota PA, Brown K, Mankertz A, Santibanez S, Shulga S, Muller CP et al (2011) Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis 204 [Suppl 1]:S514–S523CrossRefPubMed
19.
Zurück zum Zitat Pannuti CS, Morello RJ, De Moraes JC, Curti SP, Afonso AMS, Camargo MCC, De Souza VAUF (2004) Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol 11:119–122PubMedPubMedCentral Pannuti CS, Morello RJ, De Moraes JC, Curti SP, Afonso AMS, Camargo MCC, De Souza VAUF (2004) Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol 11:119–122PubMedPubMedCentral
20.
Zurück zum Zitat Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H (2008) Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 197:950–956CrossRefPubMed Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H (2008) Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 197:950–956CrossRefPubMed
Metadaten
Titel
Why does measles persist in Europe?
verfasst von
P. Plans-Rubió
Publikationsdatum
26.05.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2017
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-3011-y

Weitere Artikel der Ausgabe 10/2017

European Journal of Clinical Microbiology & Infectious Diseases 10/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.